Programmable Tumor‐Activated NanoCRISPR Platform Synergizes cGAS‐STING Activation With PD‐L1 Blockade for Potentiated Antitumor Immunity
Authors:
Open Access
- 17 June 2026
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (55) , e76550
Abstract
The cGAS‐STING pathway is an essential element of antitumor immunity. However, its activation triggers immunosuppressive molecules like PD‐L1 to feedback upregulate, which limits therapeutic efficacy. Herein, we develop a programmable tumor‐activated nanoCRISPR platform (PATROL) that co‐delivers CRISPR/Cas13a‐CARM1 plasmid and PD‐L1 blocking peptide to stimulate the cGAS‐STING‐IFN‐I pathway and diminish its immunosuppressive feedback loop, thereby improving antitumor efficacy. PATROL achieves enhanced circulation longevity, tumor‐targeting specificity, and tissue penetration due to surface modifications such as PEGylation, hyaluronic acid, and TAT peptide. At the same time, its PD‐L1 blocking peptide on the surface facilitates drug accumulation with the tumor and inhibits PD‐L1 activity. Following exposure to tumor‐associated hyaluronidase, PATROL undergoes enzyme‐triggered disassembly, surface charge reversal, rapid lysosomal escape, and significant CARM1 knockdown, leading to enhanced cGAS‐STING signaling. This bifunctional approach cooperatively reprograms the immunosuppressive tumor microenvironment, increases cytotoxic T lymphocyte infiltration, and elicits powerful antitumor immunity by simultaneously blocking PD‐1/PD‐L1 signaling and activating the cGAS‐STING‐IFN‐I pathway. PATROL exhibits significant antitumor efficacy in B16‐F10 melanoma models, successfully inhibiting tumor growth and prolonging survival. As consequently, PATROL presents an innovative therapeutic strategy that achieves effective tumor suppression by enhancing antitumor immunity through dual‐pathway activation.Keywords
This publication has 36 references indexed in Scilit:
- An Epigenetic Nanoagonist Facilitates T Cell Priming, Recruitment, and Reinvigoration in Tumors Resistant to PD‐L1 TherapyAdvanced Materials, 2025
- Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapyCancer Cell, 2025
- Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffoldBioactive Materials, 2024
- A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cellsBiomaterials, 2023
- CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategyBiomedicine & Pharmacotherapy, 2021
- Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer ImmunotherapyAdvanced Materials, 2019
- Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanomaBiomaterials, 2016
- Stem‐Loop RT‐qPCR for miRNAsCurrent Protocols in Molecular Biology, 2011
- Tissue-specific and transcription factor-mediated nuclear entry of DNAAdvanced Drug Delivery Reviews, 2009
- Intracellular routing of plasmid DNA during non-viral gene transferAdvanced Drug Delivery Reviews, 2005